HK1257542A1 - 治療與cns水腫相關的損傷或狀況的方法 - Google Patents

治療與cns水腫相關的損傷或狀況的方法 Download PDF

Info

Publication number
HK1257542A1
HK1257542A1 HK18116503.6A HK18116503A HK1257542A1 HK 1257542 A1 HK1257542 A1 HK 1257542A1 HK 18116503 A HK18116503 A HK 18116503A HK 1257542 A1 HK1257542 A1 HK 1257542A1
Authority
HK
Hong Kong
Prior art keywords
subject
sur1
hours
injury
administering
Prior art date
Application number
HK18116503.6A
Other languages
English (en)
Chinese (zh)
Inventor
Sven Martin Jacobson
Original Assignee
生物切萨皮克有限责任公司
生物切薩皮克有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 生物切萨皮克有限责任公司, 生物切薩皮克有限責任公司 filed Critical 生物切萨皮克有限责任公司
Publication of HK1257542A1 publication Critical patent/HK1257542A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK18116503.6A 2015-10-07 2016-10-07 治療與cns水腫相關的損傷或狀況的方法 HK1257542A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562238461P 2015-10-07 2015-10-07
US62/238,461 2015-10-07
PCT/US2016/055988 WO2017062765A1 (en) 2015-10-07 2016-10-07 Methods of treating injuries or conditions related to cns edema

Publications (1)

Publication Number Publication Date
HK1257542A1 true HK1257542A1 (zh) 2019-10-25

Family

ID=58488580

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18116503.6A HK1257542A1 (zh) 2015-10-07 2016-10-07 治療與cns水腫相關的損傷或狀況的方法

Country Status (15)

Country Link
US (4) US20180280325A1 (enExample)
EP (1) EP3359162B1 (enExample)
JP (4) JP7349786B2 (enExample)
KR (2) KR20240105519A (enExample)
CN (2) CN108348534A (enExample)
AU (3) AU2016335767B2 (enExample)
BR (1) BR112018006925A2 (enExample)
CA (1) CA3001321A1 (enExample)
EA (1) EA201890893A1 (enExample)
ES (1) ES2940669T3 (enExample)
HK (1) HK1257542A1 (enExample)
IL (1) IL258509B2 (enExample)
MA (1) MA45574A (enExample)
MX (1) MX392466B (enExample)
WO (1) WO2017062765A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014027983B1 (pt) 2012-05-08 2022-05-24 Aeromics, Inc Uso de inibidores de aquaporina seletivos
WO2015069961A1 (en) 2013-11-06 2015-05-14 Aeromics, Llc Novel prodrug salts
KR20240105519A (ko) * 2015-10-07 2024-07-05 레메디 파마슈티칼즈, 인크. Cns 부종과 관련한 손상 또는 병태의 치료 방법
WO2020041905A1 (en) * 2018-08-31 2020-03-05 The University Of British Columbia Methods for identifying compounds suitable for treatment of central nervous system trauma and uses of those compounds
CN113874002A (zh) * 2019-05-02 2021-12-31 生物切萨皮克有限责任公司 治疗患有中枢神经系统挫伤的受试者的方法
TW202214561A (zh) * 2020-07-17 2022-04-16 大陸商上海森輝醫藥有限公司 磺醯脲類衍生物及其醫藥用途
US12251388B1 (en) 2024-05-09 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
WO2025212189A1 (en) * 2024-04-05 2025-10-09 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema using a sur1-trpm4 channel inhibitor
WO2025212155A1 (en) * 2024-04-05 2025-10-09 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke with large vessel occlusion using a sur1-trpm4 channel inhibitor
US12251389B1 (en) 2024-04-22 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
WO2025212154A1 (en) * 2024-04-05 2025-10-09 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856360A (en) 1996-05-03 1999-01-05 Children's Hospital Medical Center Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock
DK2438913T3 (da) * 2002-03-20 2020-06-22 Univ Maryland Ikke-selektiv kationkanal i neurale celler og forbindelser, der blokerer kanalen, til anvendelse i behandling af opsvulmning af hjernen
US8980952B2 (en) * 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
US20050246000A1 (en) * 2004-05-03 2005-11-03 Seacoast Technologies, Inc. Cooled craniectomy
EP2167107B1 (en) 2007-06-22 2016-12-14 University of Maryland, Baltimore Inhibitors of ncca-atp channels for therapy
WO2009073711A1 (en) * 2007-12-04 2009-06-11 Remedy Pharmaceuticals, Inc. Improved formulations and methods for lyophilization and lyophilates provided thereby
JP6188021B2 (ja) * 2010-07-19 2017-08-30 バイオジェン チェサピーク エルエルシー グリブリドおよび他の薬剤の静脈内投与方法
KR20240105519A (ko) * 2015-10-07 2024-07-05 레메디 파마슈티칼즈, 인크. Cns 부종과 관련한 손상 또는 병태의 치료 방법

Also Published As

Publication number Publication date
AU2016335767A8 (en) 2018-06-28
IL258509B (en) 2022-12-01
IL258509B2 (en) 2023-04-01
JP2023053274A (ja) 2023-04-12
KR20180063296A (ko) 2018-06-11
JP2021073317A (ja) 2021-05-13
WO2017062765A1 (en) 2017-04-13
BR112018006925A2 (pt) 2018-10-16
US20250017880A1 (en) 2025-01-16
CA3001321A1 (en) 2017-04-13
AU2016335767B2 (en) 2022-10-06
EP3359162A1 (en) 2018-08-15
MX392466B (es) 2025-03-24
EP3359162A4 (en) 2019-08-28
IL258509A (en) 2018-05-31
JP2024164167A (ja) 2024-11-26
US20240216309A1 (en) 2024-07-04
CN108348534A (zh) 2018-07-31
US11951085B2 (en) 2024-04-09
JP7349786B2 (ja) 2023-09-25
EP3359162B1 (en) 2022-12-21
AU2022279369B2 (en) 2025-02-13
AU2022279369A1 (en) 2023-01-19
JP7592768B2 (ja) 2024-12-02
KR102681027B1 (ko) 2024-07-02
ES2940669T3 (es) 2023-05-10
KR20240105519A (ko) 2024-07-05
JP2018530564A (ja) 2018-10-18
US20180280325A1 (en) 2018-10-04
AU2025202620A1 (en) 2025-05-01
AU2016335767A1 (en) 2018-05-24
MX2018004286A (es) 2018-08-09
US20220125750A1 (en) 2022-04-28
EA201890893A1 (ru) 2018-09-28
CN115737816A (zh) 2023-03-07
MA45574A (fr) 2019-05-15

Similar Documents

Publication Publication Date Title
JP7592768B2 (ja) Ｃｎｓ浮腫に関連する損傷または状態を処置する方法
Peralta et al. Prophylactic intrathecal morphine and prevention of post–dural puncture headache: a randomized double-blind trial
Cenkowski et al. Hemodynamic effects of low-dose bupivacaine spinal anesthesia for cesarean section: A randomized controlled trial
JP2018530564A5 (enExample)
Nivatpumin et al. Ephedrine versus ondansetron in the prevention of hypotension during cesarean delivery: a randomized, double-blind, placebo-controlled trial
AU2021213064A1 (en) Therapeutic uses of tirzepatide
Sangi et al. Comparative efficacy of intravenous midazolam, midazolam-ketamine, and ketamine in reducing the prevalence of post-spinal shivering: A double-blind clinical trial
EP4615451A1 (en) Uses of bupivacaine multivesicular liposomes as stellate ganglion block for treating anxiety disorders and traumatic brain injury
AL-Morsy et al. Effect of adding nalbuphine hydrochloride versus fentanyl on the characteristic of hyperbaric bupivacaine spinal block for lower limb orthopedic surgery
Mohta et al. Comparison of potency of ephedrine and mephentermine for prevention of post-spinal hypotension in caesarean section
CN113874002A (zh) 治疗患有中枢神经系统挫伤的受试者的方法
AbdelRady et al. Role of Granisetron in preventing hypotension after spinal anaesthesia with Levobupivacaine in rheumatic patients undergoing elective cesarean section: A randomized controlled trial
Thongrong et al. Comparison of utilizing a hypertonic saline solution and mannitol to improve brain relaxation during craniotomy in patients with brain tumours: a prospective randomized controlled trial
Tong et al. 13 Pain Emergencies and Complications of Pain Treatments